Back to search

Article

RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumor immunity

2023-05-17

Abstract excerpt

<h4>Background: </h4> Although a variety of immune checkpoint monoclonal antibodies have been approved for the treatment of cancers, the low response rate of immune checkpoint inhibitors limits their wide clinical application. Therefore, to explore new and broader immunotherapy targets to improve the response rate of CD8 + T cells will provide theoretical basis for clinical treatment of refractory malignant solid...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
982e32d9-4976-551b-a2b3-d34d58c6d590
DOI
10.21203/rs.3.rs-2931210/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumor immunityDOI 10.21203/rs.3.rs-2931210/v1
Select a neighboring publication to make it the new centre.